Form 4: Labcorp Director Acquires 773 Restricted Stock Units

Labcorp Holdings Inc. Director Garheng Kong acquired 773 Restricted Stock Units, vesting on February 10, 2027, increasing his total beneficial ownership to 1,670 RSUs.

Summary

• Garheng Kong, a Director of Labcorp Holdings Inc. (LH), acquired 773 Restricted Stock Units (RSUs) on February 10, 2026.
• Each RSU represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• These 773 Restricted Stock Units will vest fully on February 10, 2027.
• Following this transaction, Garheng Kong beneficially owns an aggregate of 1,670 Restricted Stock Units.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine but positive event, as it increases director equity ownership, aligning interests with shareholders. It does not, however, indicate new operational or financial performance.

Positives

• The acquisition of Restricted Stock Units by a director increases their equity stake in the company, aligning their interests with long-term shareholder value.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned acquisition strategy.

Future Outlook

The acquired Restricted Stock Units are scheduled to vest fully on February 10, 2027, indicating a future increase in the director's direct share ownership upon vesting.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units to directors is a common practice across various industries, including healthcare diagnostics, serving as a key component of compensation packages designed to incentivize long-term commitment and align leadership interests with shareholder returns.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation for directors is a standard practice widely adopted by publicly traded companies across sectors, including major healthcare and life sciences firms like Quest Diagnostics and Thermo Fisher Scientific.
• The vesting schedule, typically over one to three years, is also consistent with industry norms for director and executive equity grants, aiming to foster long-term retention and performance alignment.

Corporate Governance

Related Party Transactions

• The grant of 773 Restricted Stock Units to Garheng Kong, a director, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Increased alignment of a director's financial interests with the company's long-term performance due to increased equity ownership.
• Management: The RSU grant serves as a component of director compensation, incentivizing continued service and strategic oversight.

Next Steps

• The 773 Restricted Stock Units are expected to vest fully on February 10, 2027, at which point they will convert into shares of Labcorp Holdings Inc. Common Stock.

Key Dates

Recommendation

This Form 4 reports a routine grant of Restricted Stock Units to a director as part of their compensation. While it increases insider ownership, it does not provide new fundamental information about the company's performance or strategic direction that would significantly alter an investment thesis. It is a standard compensation event.

Keywords

Labcorp Holdings Inc., LH, Restricted Stock Units, RSU, Insider Trading, Director Compensation, Equity Grant, Garheng Kong, Form 4